MedTrace Logo

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

NCT03361852 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-25

No results posted yet for this study

Summary

This research study is studying a novel type of FL vaccine as a possible treatment for follicular lymphoma (FL).

The agents involved in this study are:

* Rituximab
* Personalized NeoAntigen vaccine
* Poly-ICLC
* Pembrolizumab

Conditions

Interventions

DRUG

Rituximab

Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells

BIOLOGICAL

Neo Vax

Neo Vax is an experimental "viral mimic" and an activator of immunity.

DRUG

Pembrolizumab

Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy

Sponsors & Collaborators

Principal Investigators

  • Reid W Merryman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-14
Primary Completion
2026-12-31
Completion
2033-12-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03361852 on ClinicalTrials.gov